{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:28:03Z","timestamp":1790051283940,"version":"4.0.1"},"reference-count":193,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recent studies on the pathogenesis of leukemia have led to remarkable advances in disease treatment. Numerous studies have shown the potential and viability of immune responses against leukemia. In the classical pathway, this process is often initiated by the upstream activity of CD39, which hydrolyzes extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to AMP. Subsequently, CD73 acts on AMP to generate adenosine, contributing to an immunosuppressive microenvironment. However, CD73 can also utilize substrates derived from other molecules through the non-canonical NAD<jats:sup>+<\/jats:sup> pathway, specifically via the CD38\/CD203a\/CD73 axis, further enhancing adenosine production and facilitating immune escape. Targeting CD73 has shown potential in disrupting these immunosuppressive pathways, thereby enhancing anti-leukemic immune responses and improving patient outcomes. Inhibiting CD73 not only reduces the levels of immunosuppressive adenosine but also increases the efficacy of existing immunotherapies, such as PD-1\/PD-L1 inhibitors, making it a versatile therapeutic target in leukemia treatment. This review discusses the potential of CD73 as a therapeutic target and emphasizes its unique position in the immune escape mechanism of leukemia. Moreover, this review provides an overview of the current research progress and future trends, emphasizing the clinical significance of targeting CD73 and other potential therapeutic strategies in leukemia.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1486868","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:52:55Z","timestamp":1741243975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["CD73: a new immune checkpoint for leukemia treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Huan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0478","article-title":"Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells","volume":"66","author":"Lokshin","year":"2006","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00332","article-title":"Commentary: A metabolic immune checkpoint: adenosine in tumor microenvironment","volume":"7","author":"Vaupel","year":"2016","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/cells8121632","article-title":"CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents","volume":"8","author":"Costa","year":"2019","journal-title":"Cells"},{"key":"B5","article-title":"Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2\u2019-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2\u2019-deoxycoformycin","volume":"66","author":"Cass","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0167-4889(01)00069-6","article-title":"Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation","volume":"1538","author":"Schneider","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704254","article-title":"Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells","volume":"134","author":"Gessi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.281.6.C1776","article-title":"Guanine nucleosides and Jurkat cell death: roles of ATP depletion and accumulation of deoxyribonucleotides","volume":"281","author":"Batiuk","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.12.007","article-title":"Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells","volume":"75","author":"Bastin-Coyette","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1042\/bj2850345","article-title":"5\u2019-Nucleotidase: molecular structure and functional aspects","volume":"285","author":"Zimmermann","year":"1992","journal-title":"Biochem J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-006-9003-5","article-title":"The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance","volume":"2","author":"Robson","year":"2006","journal-title":"Purinergic signalling"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703136","article-title":"Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5\u2019-nucleotidase along with endogenous ATP from vascular endothelial cells","volume":"129","author":"Yegutkin","year":"2000","journal-title":"Br J Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1042\/bj20021687","article-title":"Biochemical and mass spectrometric characterization of soluble ecto-5\u2019-nucleotidase from bull seminal plasma","volume":"372","author":"Fini","year":"2003","journal-title":"Biochem J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1399-0039.1990.tb01750.x","article-title":"Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5\u2019-nucleotidase (CD73)","volume":"35","author":"Thomson","year":"1990","journal-title":"Tissue Antigens"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1042\/bj3320101","article-title":"Release of the glycosylphosphatidylinositol-anchored enzyme ecto-5\u2019-nucleotidase by phospholipase C: catalytic activation and modulation by the lipid bilayer","volume":"332","author":"Lehto","year":"1998","journal-title":"Biochem J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014806916844","article-title":"Regulation of ecto-5\u2019-nucleotidase by TNF-alpha in human endothelial cells","volume":"232","author":"Kalsi","year":"2002","journal-title":"Mol Cell Biochem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12218","article-title":"CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment","volume":"11","author":"Lu","year":"2022","journal-title":"J extracellular vesicles"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1038\/s41467-021-26134-w","article-title":"CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression","volume":"12","author":"Schneider","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-321646","article-title":"Different role of CD73 in leukocyte trafficking via blood and lymph vessels","volume":"117","author":"\u00c5lgars","year":"2011","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2012.04623.x","article-title":"CD73 and adenosine generation in the creation of regulatory microenvironments","volume":"171","author":"Regateiro","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.3390\/cancers15235706","article-title":"Unraveling the intricacies of CD73\/adenosine signaling: the pulmonary immune and stromal microenvironment in lung cancer","volume":"15","author":"Saig\u00ed","year":"2023","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242623","article-title":"CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease","volume":"42","author":"Doherty","year":"2012","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.12.4042","article-title":"Distribution of ecto-5\u2019-nucleotidase on subsets of human T and B lymphocytes as detected by indirect immunofluorescence using goat antibodies","volume":"139","author":"Thompson","year":"1987","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197151","article-title":"CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes","volume":"13","author":"Raczkowski","year":"2018","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150078","article-title":"CD73 expressed on \u03b3\u03b4 T cells shapes their regulatory effect in experimental autoimmune uveitis","volume":"11","author":"Liang","year":"2016","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400336","article-title":"A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production","volume":"193","author":"Kaku","year":"2014","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20111696","article-title":"A germinal center-independent pathway generates unswitched memory B cells early in the primary response","volume":"209","author":"Taylor","year":"2012","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803474","article-title":"High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population","volume":"185","author":"Moncrieffe","year":"2010","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-065X.1998.tb01574.x","article-title":"Ecto-enzyme and signaling functions of lymphocyte CD73","volume":"161","author":"Resta","year":"1998","journal-title":"Immunol Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.136.2.421","article-title":"Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells","volume":"136","author":"Airas","year":"1997","journal-title":"J Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3109","article-title":"CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression","volume":"70","author":"Jin","year":"2010","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45559","article-title":"CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice","volume":"121","author":"Wang","year":"2011","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4246","article-title":"CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis","volume":"71","author":"Stagg","year":"2011","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v113.8","article-title":"CD73 facilitates invadopodia formation and boosts Malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway","volume":"113","author":"Xue","year":"2022","journal-title":"Cancer science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.728200","article-title":"CD73 severed as a potential prognostic marker and promote lung cancer cells migration via enhancing EMT progression","volume":"12","author":"Gao","year":"2021","journal-title":"Front Genet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e12108","DOI":"10.1016\/j.heliyon.2022.e12108","article-title":"Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma","volume":"8","author":"Dai","year":"2022","journal-title":"Heliyon"},{"key":"B38","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI0215337","article-title":"Ecto-5\u2019-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia","volume":"110","author":"Synnestvedt","year":"2002","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.019","article-title":"Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression","volume":"36","author":"Chalmin","year":"2012","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838437","article-title":"IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier","volume":"38","author":"Niemel\u00e4","year":"2008","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003671","article-title":"Tissue-resident ecto-5\u2019 nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain","volume":"188","author":"Petrovic-Djergovic","year":"2012","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939741","article-title":"NTPDase1 governs P2X7-dependent functions in murine macrophages","volume":"40","author":"L\u00e9vesque","year":"2010","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0767","article-title":"Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma","volume":"67","author":"Bergmann","year":"2007","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737793","article-title":"IFN-beta protects from vascular leakage via up-regulation of CD73","volume":"37","author":"Kiss","year":"2007","journal-title":"Eur J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"460654","DOI":"10.1155\/2014\/460654","article-title":"The roles of CD73 in cancer","volume":"2014","author":"Gao","year":"2014","journal-title":"BioMed Res Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1410","article-title":"Tumor-selective altered glycosylation and functional attenuation of CD73 in human hepatocellular carcinoma","volume":"3","author":"Alcedo","year":"2019","journal-title":"Hepatol Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6626","article-title":"Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity","volume":"9","author":"Fu","year":"2023","journal-title":"Sci Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-006-9000-8","article-title":"Ecto-5\u2019-nucleotidase: Structure function relationships","volume":"2","author":"Str\u00e4ter","year":"2006","journal-title":"Purinergic signalling"},{"key":"B50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.04.036","article-title":"NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model","volume":"585","author":"Vaisitti","year":"2011","journal-title":"FEBS letters"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18388\/abp.2012_2105","article-title":"Dual, enzymatic and non-enzymatic, function of ecto-5\u2019-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells","volume":"59","author":"Sadej","year":"2012","journal-title":"Acta Biochim Polonica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13046-022-02511-1","article-title":"Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist","volume":"41","author":"Bai","year":"2022","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2022.2094593","article-title":"Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4(+) T-cell hypersecretion of IL-17A and IL-8 in humans","volume":"45","author":"Tokano","year":"2022","journal-title":"Immunol Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100117","article-title":"The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6","volume":"186","author":"Wilson","year":"2011","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J immunotherapy cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8(+) T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052406","article-title":"Purine release, metabolism, and signaling in the inflammatory response","volume":"37","author":"Linden","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.tranon.2021.101047","article-title":"The role of exosomal PD-L1 in tumor immunotherapy","volume":"14","author":"Wang","year":"2021","journal-title":"Trans Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J immunotherapy Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","article-title":"Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03219-z","article-title":"Functional expression of CD73 on human natural killer cells","volume":"71","author":"Chambers","year":"2022","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/carcin\/bgy154","article-title":"Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer","volume":"40","author":"Koivisto","year":"2019","journal-title":"Carcinogenesis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/01.cmr.0000215030.69823.11","article-title":"Expression of ecto-5\u2019-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma","volume":"16","author":"Sadej","year":"2006","journal-title":"Melanoma Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176390","article-title":"Pharmacological suppression of the OTUD4\/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers","volume":"134","author":"Zhu","year":"2024","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"176328","DOI":"10.1016\/j.ejphar.2024.176328","article-title":"Investigation of co-treatment multi-targeting approaches in breast cancer cell lines","volume":"966","author":"Longaray","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"118389","DOI":"10.1016\/j.lfs.2020.118389","article-title":"Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways","volume":"259","author":"Giatromanolaki","year":"2020","journal-title":"Life Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.CIR-22-0260","article-title":"CD73 inhibits cGAS-STING and cooperates with CD39 to promote pancreatic cancer","volume":"11","author":"Jacoberger-Foissac","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2022.04.025","article-title":"The regulation of CD73 in non-small cell lung cancer","volume":"170","author":"Han","year":"2022","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2174\/1573406416666200925141703","article-title":"Identification and expression analysis of CD73 inhibitors in cervical cancer","volume":"17","author":"Iqbal","year":"2021","journal-title":"Medicinal Chem (Shariqah (United Arab Emirates))"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/0e219081-9218-480c-aa54-1142a68aed14","article-title":"Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5\u2019NT\/CD73 in metastasis as potential prognostic factor","volume":"7","author":"Cappellari","year":"2012","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2007.04.058","article-title":"Indomethacin stimulates activity and expression of ecto-5\u2019-nucleotidase\/CD73 in glioma cell lines","volume":"569","author":"Bernardi","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","article-title":"Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape","volume":"4","author":"Montalb\u00e1n Del Barrio","year":"2016","journal-title":"J Immunotherapy Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128895","article-title":"CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment","volume":"130","author":"Neo","year":"2020","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02820-4","article-title":"CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma","volume":"70","author":"Rocha","year":"2021","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13346","article-title":"Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC","volume":"11","author":"Ishii","year":"2020","journal-title":"Thorac cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"122129","DOI":"10.1016\/j.lfs.2023.122129","article-title":"Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells","volume":"332","author":"Su","year":"2023","journal-title":"Life Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9944847","DOI":"10.1155\/2022\/9944847","article-title":"CD73 (NT5E) promotes the proliferation and metastasis of lung adenocarcinoma through the EGFR\/AKT\/mTOR pathway","volume":"2022","author":"Zhang","year":"2022","journal-title":"BioMed Res Int"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.969034","article-title":"Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma","volume":"13","author":"Shen","year":"2022","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001161","article-title":"The prognostic impact of the immune signature in head and neck squamous cell carcinoma","volume":"13","author":"Baysal","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-019-0724-7","article-title":"CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K\/AKT signaling by inducing Rap1-mediated membrane localization of P110\u03b2 and predicts poor prognosis","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.v234.7","article-title":"Ecto-5\u2019-nucleotidase (CD73) is a potential target of hepatocellular carcinoma","volume":"234","author":"Shali","year":"2019","journal-title":"J Cell Physiol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2553","article-title":"CD73-dependent adenosine signaling through adora2b drives immunosuppression in ductal pancreatic cancer","volume":"83","author":"Faraoni","year":"2023","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2021.03.018","article-title":"Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival","volume":"21","author":"Zhao","year":"2021","journal-title":"Pancreatology: Off J Int Assoc Pancreatology (IAP) [et al]"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-018-01742-0","article-title":"The distinct role of CD73 in the progression of pancreatic cancer","volume":"97","author":"Zhou","year":"2019","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.v24.15","article-title":"CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer","volume":"24","author":"Chen","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201537R","article-title":"CD73-generated extracellular adenosine promotes resolution of neutrophil-mediated tissue injury and restrains metaplasia in pancreatitis","volume":"37","author":"O\u2019Brien","year":"2023","journal-title":"FASEB journal: Off Publ Fed Am Societies Exp Biol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1159\/000534677","article-title":"Exploring the expression of adenosine pathway-related markers CD73 and CD39 in colorectal and pancreatic carcinomas characterized by multiplex immunofluorescence: A pilot study","volume":"91","author":"Lima","year":"2023","journal-title":"Pathobiology: J immunopathology Mol Cell Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2018.0183","article-title":"Mesenchymal stromal cells derived from normal cervix and cervical cancer tumors increase CD73 expression in cervical cancer cells through TGF-\u03b21 production","volume":"28","author":"\u00c1vila-Ibarra","year":"2019","journal-title":"Stem Cells Dev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-021-03100-x","article-title":"CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas","volume":"479","author":"Monteiro","year":"2021","journal-title":"Virchows Archiv: an Int J pathology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.3390\/cancers12103042","article-title":"CD73 overexpression promotes progression and recurrence of papillary thyroid carcinoma","volume":"12","author":"Jeong","year":"2020","journal-title":"Cancers"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2446","article-title":"CD73 promotes cervical cancer growth via EGFR\/AKT1 pathway","volume":"11","author":"Liu","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.006","article-title":"Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer","volume":"157","author":"He","year":"2021","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13124","article-title":"Mesenchymal stem cell marker expression in gastric cancer stroma","volume":"39","author":"Numakura","year":"2019","journal-title":"Anticancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867167","article-title":"Inversed ratio of CD39\/CD73 expression on \u03b3\u03b4 T cells in HIV versus healthy controls correlates with immune activation and disease progression","volume":"13","author":"Kolbe","year":"2022","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010378","article-title":"Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+ T cells of HIV-infected individuals","volume":"18","author":"Shahbaz","year":"2022","journal-title":"PloS pathogens"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001467","article-title":"Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma","volume":"8","author":"Tripathi","year":"2020","journal-title":"J immunotherapy Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-013-1752-1","article-title":"NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer","volume":"355","author":"Xiong","year":"2014","journal-title":"Cell Tissue Res"},{"key":"B107","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12957-023-02970-6","article-title":"Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma","volume":"21","author":"Sun","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/jso.v106.2","article-title":"High expression of CD73 as a poor prognostic biomarker in human colorectal cancer","volume":"106","author":"Wu","year":"2012","journal-title":"J Surg Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12967-017-1348-8","article-title":"Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab","volume":"15","author":"Morello","year":"2017","journal-title":"J Trans Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.3390\/cancers14225663","article-title":"Identification of CD73 as a novel biomarker encompassing the tumor microenvironment, prognosis, and therapeutic responses in various cancers","volume":"14","author":"Tang","year":"2022","journal-title":"Cancers"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0770","article-title":"MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer","volume":"82","author":"Yoshida","year":"2022","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1179022","article-title":"CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases","volume":"14","author":"Petruk","year":"2023","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1038\/s41598-021-85379-z","article-title":"CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer","volume":"11","author":"Petruk","year":"2021","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12929-023-00968-6","article-title":"5\u2019-Ectonucleotidase CD73\/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells","volume":"30","author":"Shi","year":"2023","journal-title":"J Biomed science"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00698","article-title":"Targeting the immunomodulatory CD73\/adenosine system to improve the therapeutic gain of radiotherapy","volume":"10","author":"de Leve","year":"2019","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.982821","article-title":"SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC","volume":"13","author":"Hasmim","year":"2022","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2015.2125","article-title":"Pharmacological improvement and preclinical evaluation of methotrexate-loaded lipid-core nanocapsules in a glioblastoma model","volume":"11","author":"Figueir\u00f3","year":"2015","journal-title":"J Biomed nanotechnology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-021-09775-w","article-title":"Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth","volume":"17","author":"Lopes","year":"2021","journal-title":"Purinergic signalling"},{"key":"B119","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1118-18.2019","article-title":"CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A(2B) adenosine receptor signaling","volume":"39","author":"Yan","year":"2019","journal-title":"J neuroscience: Off J Soc Neurosci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4410","article-title":"Clonal evolution in leukemia","volume":"23","author":"Ferrando","year":"2017","journal-title":"Nat Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1148\/50.3.387","article-title":"Chemotherapy in human lymphomas, leukemias, and allied disorders of the hemopoietic system","volume":"50","author":"Spurr","year":"1948","journal-title":"Radiology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1486064","article-title":"Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5457.1442","article-title":"Translating stem and progenitor cell biology to the clinic: barriers and opportunities","volume":"287","author":"Weissman","year":"2000","journal-title":"Sci (New York NY)"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic stem cell transplantation: A historical and scientific overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2008.238","article-title":"The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation","volume":"22","author":"Tavor","year":"2008","journal-title":"Leukemia"},{"key":"B136","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1200\/JCO.2019.37.15_suppl.7001","article-title":"A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML)","volume":"37","author":"Kovacsovics","year":"2019","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.02.017","article-title":"Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells","volume":"31","author":"Liesveld","year":"2007","journal-title":"Leukemia Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6808","article-title":"Peptides and small molecules blocking the CXCR4\/CXCL12 axis overcome bone marrow\u2212induced chemoresistance in acute leukemias","volume":"41","author":"Pillozzi","year":"2019","journal-title":"Oncol Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3693","article-title":"CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice","volume":"64","author":"Tavor","year":"2004","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2018-99-114286","article-title":"Uproleselan (GMI-1271), an E-selectin antagonist, improves the efficacy and safety of chemotherapy in relapsed\/refractory (R\/R) and newly diagnosed older patients with acute myeloid leukemia: final, correlative, and subgroup analyses","volume":"132","author":"DeAngelo","year":"2018","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-406272","article-title":"Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy","volume":"121","author":"Hsieh","year":"2013","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.v76b:2","article-title":"Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection","volume":"76","author":"DiGiuseppe","year":"2009","journal-title":"Cytometry Part B Clin cytometry"},{"key":"B144","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","article-title":"Leukaemia hijacks a neural mechanism to invade the central nervous system","volume":"560","author":"Yao","year":"2018","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.312","article-title":"The complexity of integrins in cancer and new scopes for therapeutic targeting","volume":"115","author":"Hamidi","year":"2016","journal-title":"Br J cancer"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00262","article-title":"A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/PPO.0000000000000376","article-title":"Adoptive cell therapy for acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"25","author":"Lulla","year":"2019","journal-title":"Cancer J (Sudbury Mass)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867103","article-title":"Leukemia\u2019s next top model? Syngeneic models to advance adoptive cellular therapy","volume":"13","author":"Zoine","year":"2022","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2165\/00003495-197611050-00003","article-title":"Drug-induced anaemias","volume":"11","author":"Girdwood","year":"1976","journal-title":"Drugs"},{"key":"B152","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.3390\/cancers13215319","article-title":"Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: tangle or chance","volume":"13","author":"Ciciarello","year":"2021","journal-title":"Cancers"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.943994","article-title":"The consistency between the Chinese essential medicines list and treatment guidelines-taking oncology medicines as an example","volume":"10","author":"Cheng","year":"2022","journal-title":"Front Public Health"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.05.009","article-title":"Recent progress on targeting leukemia stem cells","volume":"26","author":"Ma","year":"2021","journal-title":"Drug Discovery Today"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.3390\/cancers14133130","article-title":"CD73 promotes chronic lymphocytic leukemia","volume":"14","author":"Allard","year":"2022","journal-title":"Cancers"},{"key":"B156","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-023-00375-5","article-title":"Depletion of polyfunctional CD26(high)CD8(+) T cells repertoire in chronic lymphocytic leukemia","volume":"12","author":"Bozorgmehr","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.jbc.2023.104587","article-title":"ATP and its metabolite adenosine cooperatively upregulate the antigen-presenting molecules on dendritic cells leading to IFN-\u03b3 production by T cells","volume":"299","author":"Furuta","year":"2023","journal-title":"J Biol Chem"},{"key":"B158","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.critrevonc.2018.03.022","article-title":"Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia","volume":"126","author":"Cai","year":"2018","journal-title":"Crit Rev oncology\/hematology"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.190132","article-title":"Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways","volume":"103","author":"Abruzzo","year":"2018","journal-title":"Haematologica"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-022-09841-x","article-title":"NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia","volume":"18","author":"da Silva Nunes","year":"2022","journal-title":"Purinergic signalling"},{"key":"B161","doi-asserted-by":"publisher","first-page":"112429","DOI":"10.1016\/j.jim.2018.03.005","article-title":"Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia","volume":"475","author":"S\u0119dek","year":"2019","journal-title":"J Immunol Methods"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1070153","article-title":"The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia","volume":"57","author":"Wang","year":"2016","journal-title":"Leukemia lymphoma"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21486","article-title":"Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000","volume":"94","author":"Tembhare","year":"2018","journal-title":"Cytometry Part B Clin cytometry"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw4304","article-title":"Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML","volume":"5","author":"Jakobsen","year":"2019","journal-title":"Sci Adv"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.17","article-title":"Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration","volume":"5","author":"Huang","year":"2015","journal-title":"Blood Cancer J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3868","article-title":"Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-\u03b1","volume":"21","author":"Mascanfroni","year":"2015","journal-title":"Nat Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"109981","DOI":"10.1016\/j.celrep.2021.109981","article-title":"The cell-surface 5\u2019-nucleotidase CD73 defines a functional T memory cell subset that declines with age","volume":"37","author":"Fang","year":"2021","journal-title":"Cell Rep"},{"key":"B169","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2326-6066.CIR-14-0075","article-title":"Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists","volume":"2","author":"Sitkovsky","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1189-3","article-title":"Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1\u03b1-dependent and extracellular adenosine-mediated tumor protection","volume":"92","author":"Hatfield","year":"2014","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.570041","article-title":"Targeting hypoxia-A2A adenosinergic immunosuppression of antitumor T cells during cancer immunotherapy","volume":"11","author":"Steingold","year":"2020","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00192","article-title":"Functional mechanisms of treg in the context of HIV infection and the janus face of immune suppression","volume":"7","author":"L\u00f3pez-Abente","year":"2016","journal-title":"Front Immunol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91954","article-title":"Induction of antiinflammatory purinergic signaling in activated human iNKT cells","volume":"3","author":"Yu","year":"2018","journal-title":"JCI Insight"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0707","article-title":"CD73 promotes resistance to HER2\/erbB2 antibody therapy","volume":"77","author":"Turcotte","year":"2017","journal-title":"Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0395","article-title":"MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy","volume":"77","author":"Reinhardt","year":"2017","journal-title":"Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1930391","DOI":"10.1080\/2162402X.2021.1930391","article-title":"Increased frequency of TIGIT(+)CD73-CD8(+) T cells with a TOX(+) TCF-1low profile in patients with newly diagnosed and relapsed AML","volume":"10","author":"Brauneck","year":"2021","journal-title":"Oncoimmunology"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00813","article-title":"Controlling the immune suppressor: transcription factors and microRNAs regulating CD73\/NT5E","volume":"9","author":"Korda\u00df","year":"2018","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","article-title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation","volume":"42","author":"Sun","year":"2023","journal-title":"J Exp Clin Cancer research: CR"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M809275200","article-title":"Adenosine signaling mediates SUMO-1 modification of IkappaBalpha during hypoxia and reoxygenation","volume":"284","author":"Liu","year":"2009","journal-title":"J Biol Chem"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1678780","DOI":"10.1155\/2020\/1678780","article-title":"Detection of CD39 and a highly glycosylated isoform of soluble CD73 in the plasma of patients with cervical cancer: correlation with disease progression","volume":"2020","author":"Mu\u00f1\u00f3z-God\u00ednez","year":"2020","journal-title":"Mediators inflammation"},{"key":"B181","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2019.37.15_suppl.2505","article-title":"Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers","volume":"37","author":"Luke","year":"2019","journal-title":"J Clin Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00525","article-title":"Discovery of AB680: A potent and selective inhibitor of CD73","volume":"63","author":"Lawson","year":"2020","journal-title":"J medicinal Chem"},{"key":"B183","doi-asserted-by":"publisher","first-page":"e2302498","DOI":"10.1002\/advs.202302498","article-title":"Tumor microenvironment responsive CD8(+) T cells and myeloid-derived suppressor cells to trigger CD73 inhibitor AB680-based synergistic therapy for pancreatic cancer","volume":"10","author":"Chen","year":"2023","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B184","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.2021.39.15_suppl.2511","article-title":"Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer","volume":"39","author":"Robert","year":"2021","journal-title":"JCO"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B186","doi-asserted-by":"publisher","first-page":"TPS2675","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2675","article-title":"A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1\/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors","volume":"39","author":"Markman","year":"2021","journal-title":"JCO"},{"key":"B187","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.trecan.2016.01.003","article-title":"Anti-CD73 in cancer immunotherapy: awakening new opportunities","volume":"2","author":"Antonioli","year":"2016","journal-title":"Trends cancer"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0107","article-title":"A novel antagonistic CD73 antibody for inhibition of the immunosuppressive adenosine pathway","volume":"20","author":"Wurm","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B189","doi-asserted-by":"publisher","first-page":"189005","DOI":"10.1016\/j.bbcan.2023.189005","article-title":"Adenosine in cancer immunotherapy: Taking off on a new plane","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-019-09918-y","article-title":"The inhibition of CD39 and CD73 cell surface ectonucleotidases by small molecular inhibitors enhances the mobilization of bone marrow residing stem cells by decreasing the extracellular level of adenosine","volume":"15","author":"Adamiak","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: expression","volume":"15","author":"Sheth","year":"2014","journal-title":"Funct Regul"},{"key":"B192","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/ijms19030784","article-title":"The inside story of adenosine","volume":"19","author":"Camici","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1486868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:53:02Z","timestamp":1741243982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1486868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":193,"alternative-id":["10.3389\/fimmu.2025.1486868"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1486868","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"article-number":"1486868"}}